Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast



This report contains a summary of the analyst consensus forecasts available in the It Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This 27-page report gives important, expert insight you wont find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
- Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the COVID-19 disease space
- Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

Reasons to Buy

- Analysis of COVID-19 analyst consensus sales forecasts
- Overview of Pipeline portfolio of companies involved in COVID-19 disease space
- Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs
1 (PowerPoint Deck)
1 COVID-19 Global Analyst Consensus Sales Forecast
2 Gilead Sciences Inc.
2.1 Gilead Sciences Pipeline
2.2 Global Analyst Consensus Sales Forecast - Gilead Sciences Remdesivir
3 CanSino Biologic Inc.
3.1 CanSino Biologic Pipeline
3.2 Global Analyst Consensus Sales Forecast - CanSino Biologics COVID-19 Vaccine
4 Cytodyn Inc.
4.1 Global Analyst Consensus Sales Forecast - Cytodyns Leronlimab
4.2 Archived Global Analyst Consensus Sales Forecast - Cytodyns Leronlimab
5 Key Findings
6 Appendix
6.1 Methodology
6.2 Related Reports
6.3 About the Authors
6.4 About GlobalData
6.5 Contact Us

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a

USD 1495 View Report

Coronavirus Disease Vaccines (COVID-19 Vaccines)

Coronavirus Disease Vaccines (COVID-19 Vaccines)The sprint to advance a COVID-19 vaccine is hotly contested. More than 100 vaccines are in preclinical testing, according to 23 companies have moved their candidates

USD 495 View Report

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a

USD 1495 View Report

Coronavirus Disease Vaccines (COVID-19 Vaccines)

Coronavirus Disease Vaccines (COVID-19 Vaccines)The sprint to advance a COVID-19 vaccine is hotly contested. More than 100 vaccines are in preclinical testing, according to 23 companies have moved their candidates

USD 495 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available